Responses to analogues of growth hormone-releasing hormone in normal subjects, and in growth-hormone deficient children and young adults

Clin Endocrinol (Oxf). 1984 Sep;21(3):321-30. doi: 10.1111/j.1365-2265.1984.tb03477.x.


Three analogues of growth hormone-releasing hormone (GHRH) have been compared in normal subjects. GHRH(1-29)NH2 is equipotent to GHRH(1-40); increasing doses from 10-200 micrograms per subject augments the duration of stimulated growth hormone (GH) release, but the peak serum GH shows only a poor correlation with dose. The derivative D-Ala2-GHRH(1-29)NH2 is no more potent than the unsubstituted GHRH(1-29)NH2. In 20 children and young adults with growth hormone deficiency by conventional criteria, eight showed normal or only slightly subnormal peak serum GH responses to GHRH(1-40) or GHRH(1-29)NH2. These included two patients with tumours of the hypothalamus, as well as six with idiopathic isolated growth hormone deficiency or panhypopituitarism. A poor response to GHRH was generally seen in patients on long-term GH therapy. Priming with GHRH, in either a single bolus or a continuous infusion, did not increase the GH response to GHRH. It is concluded that GHRH(1-29)NH2 is a useful analogue in the testing of GH reserve in patients with growth hormone deficiency, and has considerable potential for long-term therapy.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Child
  • Dose-Response Relationship, Drug
  • Female
  • Growth Hormone / blood*
  • Growth Hormone / deficiency
  • Growth Hormone-Releasing Hormone / analogs & derivatives*
  • Growth Hormone-Releasing Hormone / pharmacology*
  • Humans
  • Male
  • Peptide Fragments / pharmacology*
  • Sermorelin


  • Peptide Fragments
  • somatotropin releasing factor 40
  • somatotropin-releasing hormone (1-29)amide, Ala(2)-
  • Sermorelin
  • Growth Hormone
  • Growth Hormone-Releasing Hormone